|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/56 | (2006.01) |
| A61K 31/56 | (2013.01) | ||
| A61P 15/00 | (2006.01) | ||
| A61P 15/00 | (2018.01) | ||
| A61P 5/24 | (2018.01) | ||
| A61P 7/00 | (2018.01) |
| (11) | Number of the document | 3653213 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19199484.7 |
| Date of filing the European patent application | 2014-10-07 | |
| (97) | Date of publication of the European application | 2020-05-20 |
| (45) | Date of publication and mention of the grant of the patent | 2024-02-21 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201361887643 P | 2013-10-07 | US |
| (72) |
WOTTON, Paul K. , US
JAFFE, Jonathan , US
|
| (73) |
Antares Pharma, Inc. ,
100 Princeton South
Corporate Center
Suite 300, Ewing, New Jersey 08628,
US
|
| (54) | HEMATOCRIT MODULATION THROUGH NEEDLE ASSISTED JET INJECTION OF TESTOSTERONE |
| HEMATOCRIT MODULATION THROUGH NEEDLE ASSISTED JET INJECTION OF TESTOSTERONE |